Literature DB >> 7915910

Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

E Sykes1, K Woodburn, D Decker, D Kessel.   

Abstract

The clinical formulation of the anti-tumour agent Taxol involves the use of a mixture of ethanol and Cremophor EL. Gel electrophoresis and density-gradient ultracentrifugation were used to detect effects of Taxol infusions on serum lipoproteins. Use of the Cremophor vehicle results in a decrease in the electrophoretic mobility of serum lipoproteins along with the appearance of a lipoprotein dissociation product. These effects persist during a 24 h infusion and for at least 1.5 h afterwards, and can be reproduced in vitro using purified high-density lipoprotein (HDL) or low-density lipoprotein (LDL). In control serum, Taxol binds to albumin > HDL, but after serum is exposed to Cremophor EL in vitro or in vivo substantial binding of Taxol to the lipoprotein dissociation product(s) was observed. The latter could represent an important factor in taxol biodistribution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915910      PMCID: PMC2033337          DOI: 10.1038/bjc.1994.317

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors.

Authors:  A R Morgan; G M Garbo; R W Keck; S H Selman
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

2.  Sequential flotation ultracentrifugation.

Authors:  V N Schumaker; D L Puppione
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Enzymatic methods for quantification of lipoprotein lipids.

Authors:  G R Warnick
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Unusual serum lipoprotein abnormality induced by the vehicle of miconazole.

Authors:  A G Bagnarello; L A Lewis; M C McHenry; A J Weinstein; H K Naito; A J McCullough; R J Lederman; T L Gavan
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

5.  Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

Authors:  L Webster; M Linsenmeyer; M Millward; C Morton; J Bishop; D Woodcock
Journal:  J Natl Cancer Inst       Date:  1993-10-20       Impact factor: 13.506

6.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

Authors:  D M Woodcock; S Jefferson; M E Linsenmeyer; P J Crowther; G M Chojnowski; B Williams; I Bertoncello
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

7.  Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line.

Authors:  D S Chervinsky; M L Brecher; M J Hoelcle
Journal:  Anticancer Res       Date:  1993 Jan-Feb       Impact factor: 2.480

8.  Phase I clinical and pharmacokinetic study of taxol.

Authors:  P H Wiernik; E L Schwartz; J J Strauman; J P Dutcher; R B Lipton; E Paietta
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

9.  The alteration of plasma lipoproteins by cremophor EL.

Authors:  K Woodburn; D Kessel
Journal:  J Photochem Photobiol B       Date:  1994-03       Impact factor: 6.252

10.  The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

Authors:  E Friche; P B Jensen; M Sehested; E J Demant; N N Nissen
Journal:  Cancer Commun       Date:  1990
View more
  11 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo.

Authors:  Suna He; Zheng Cui; Dong Mei; Hua Zhang; Xueqing Wang; Wenbing Dai; Qiang Zhang
Journal:  AAPS PharmSciTech       Date:  2012-05-30       Impact factor: 3.246

3.  High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.

Authors:  Padma Kadiyala; Dan Li; Fernando M Nuñez; David Altshuler; Robert Doherty; Rui Kuai; Minzhi Yu; Neha Kamran; Marta Edwards; James J Moon; Pedro R Lowenstein; Maria G Castro; Anna Schwendeman
Journal:  ACS Nano       Date:  2019-02-11       Impact factor: 15.881

Review 4.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.

Authors:  Charity D Scripture; William D Figg; Alex Sparreboom
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

6.  Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

Authors:  L K Webster; E J Cosson; K H Stokes; M J Millward
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

7.  Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance.

Authors:  Jelena R Mitrović; Branka Divović; Daniel E Knutson; Jelena B Đoković; Predrag J Vulić; Danijela V Randjelović; Vladimir D Dobričić; Bojan R Čalija; James M Cook; Miroslav M Savić; Snežana D Savić
Journal:  Eur J Pharm Sci       Date:  2020-06-18       Impact factor: 5.112

8.  Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity.

Authors:  Po-Chang Chiang; Stephen Gould; Michelle Nannini; Ann Qin; Yuzhong Deng; Alfonso Arrazate; Kimberly R Kam; Yingqing Ran; Harvey Wong
Journal:  Nanoscale Res Lett       Date:  2014-04-01       Impact factor: 4.703

9.  Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.

Authors:  Lulu Cai; Xianhuo Wang; Wenwen Wang; Neng Qiu; Jiaolin Wen; Xingmei Duan; Xia Li; Xiang Chen; Li Yang; Zhiyong Qian; Yuquan Wei; Lijuan Chen
Journal:  Int J Nanomedicine       Date:  2012-08-14

10.  Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe.

Authors:  Rehmana Rashid; Dong Wuk Kim; Abid Mehmood Yousaf; Omer Mustapha; Jong Hyuck Park; Chul Soon Yong; Yu-Kyoung Oh; Yu Seok Youn; Jong Oh Kim; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.